2. Epigenetics Metabolic Enzyme/Protease Apoptosis
  3. Epigenetic Reader Domain Phosphatase c-Myc Apoptosis
  4. BRD4-IN-11

BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis.

For research use only. We do not sell to patients.

BRD4-IN-11

BRD4-IN-11 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BRD4-IN-11 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis[1].

IC50 & Target[1]

BRD4 (BD1)

26.35 nM (IC50)

BRD4 (BD2)

72.81 nM (IC50)

In Vitro

BRD4-IN-11 (Compound 11r) exhibits inhibition of LX-2 cells[1].

BRD4-IN-11 (0.5-2.0 μM, 48 h) reduces the apoptosis rate, inhibits the expression of CDC25B, α-SMA, and c-Myc, and fibronectin in Carbon tetrachloride (CCl4) (HY-Y0298)-treated LO2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BRD4-IN-11 Related Antibodies
In Vivo

BRD4-IN-11 (Compound 11r) (15-30 mg/kg, p.o., once a day, 3 days) prevents liver injury and fibrosis through dual mechanisms: inhibition of hepatocyte apoptosis and suppression of fibrotic protein expression in CCl4-induced murine liver injure model[1].

BRD4-IN-11 (15-30 mg/kg, p.o., once a day, 15 days) prevents lung fibrosis in Bleomycin (BLM) (HY-108345) induced pulmonary fibrosis (PF) model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CCl4-induced (1 mg/kg, i.p.) male C57BL/6J mice (6-7weeks old) hepatic fibrosis model[1]
Dosage: 15 mg/kg, 30 mg/kg
Administration: p.o., once a day, 3 days
Result: Alleviated CCl4-induced liver fibrosis, reduced collagen deposition in liver tissue and the increased expression of fibrosis biomarkers (type I collagen and α-SMA) in CCl4-treated mice, and alleviated CCl4-induced massive hepatocyte apoptosis.
Reduced liver weight coefficient and AST, ALT and TG levels at 30 mg/kg.
Had a safer and more effective ameliorative effect on CCl4-induced organ toxicity than JQ-1 (HY-78695), and that high dose is more effective than low dose.
Animal Model: BLM-induced (2 mg/kg, injected into the trachea) male C57BL/6J mice (6-7weeks old) PF model[1]
Dosage: 15 mg/kg, 30 mg/kg
Administration: p.o., once a day, 15 days
Result: Reduced lung coefficient (lung weight/body weight ratio) and hydroxyproline content (a specific marker of collagen deposition and fibrosis severity), indicating effective attenuation of fibrosis at the molecular level.
Reduced inflammatory cell infiltration, decreased collagen deposition in lung tissue, and suppressed the expression of key fibrosis markers (i.e., collagen I and α-SMA) in BLM-injured lung tissue.
Molecular Weight

785.39

Formula

C40H37ClN4O5S3
SMILES

CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(OC5=CC=C(C=C5)OCCCCCCOC6=CC=C(C=C6)C7=CC(SS7)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BRD4-IN-11 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BRD4-IN-11Epigenetic Reader DomainPhosphatasec-MycApoptosisMycInhibitorLX-2 cellsLO2 cellsCCl4-induced murine liver injure modelBLM induced PF modelinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BRD4-IN-11
Cat. No.:
HY-175033
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.